A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
CompletedPhase 3Results postedLast updated 22 September 2025
What this trial tests
Phase 3 trial testing Atezolizumab in Carcinoma, Hepatocellular in 152 participants. Completed in 13 August 2024.
18 and older, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/HaemorrhagePrimary· Up to approximately 47.6 months
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity of AEs was graded using NCI CTCAE v5.0. Grade 3=Severe/medically significant but not immediately life-threatening, hospitalization/prolongation of hospitalization indicated; disa
Grade 3
Group
Value
95% CI
Atezolizumab + Bevacizumab
17
Grade 4
Group
Value
95% CI
Atezolizumab + Bevacizumab
3
Grade 5
Group
Value
95% CI
Atezolizumab + Bevacizumab
2
Overall Survival (OS)Secondary· Up to approximately 47.6 months
OS was defined as the time from initiation of study treatment to death from any cause. Kaplan-Meier (K-M) method was used to estimate the OS.
Group
Value
95% CI
Atezolizumab + Bevacizumab
20.76
16.85 – 26.35
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Secondary· Up to approximately 47.6 months
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as AEs with onset date on or after the start of the first study treatment component. Number of participants with any TEAEs are reported here.
Group
Value
95% CI
Atezolizumab + Bevacizumab
144
Progression-free Survival (PFS)Secondary· Up to approximately 47.6 months
PFS was defined as the time from initiation of study treatment to the first occurrence of disease progression (PD) or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm). Participants alive and w
Group
Value
95% CI
Atezolizumab + Bevacizumab
8.80
7.89 – 11.24
Objective Response Rate (ORR)Secondary· Up to approximately 47.6 months
ORR was defined as the percentage of participants with complete or partial response (CR or PR), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.
Group
Value
95% CI
Atezolizumab + Bevacizumab
28.29
0.2173 – 0.3592
Time to Progression (TTP)Secondary· Up to approximately 47.6 months
TTP was defined as the time from initiation of study treatment to the first occurrence of PD, as determined by the investigator according to RECIST v1.1. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants without any PD were censored at the last assessment date. K-M method was used to estimate the TTP.
Group
Value
95% CI
Atezolizumab + Bevacizumab
11.24
8.48 – 15.77
Duration of Response (DOR)Secondary· Up to approximately 47.6 months
DOR was defined as the time from the first occurrence of a documented objective response (CR or PR) to PD or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at pri
Group
Value
95% CI
Atezolizumab + Bevacizumab
17.35
13.54 – 27.24
Post-progression Survival (PPS)Secondary· Up to approximately 47.6 months
PPS was defined as the time from the first occurrence of PD as determined by the investigator according to RECIST v1.1 to death from any cause. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. Participants who were alive were censored at the last assessment date. K-M method was used to estimate the PPS.
Group
Value
95% CI
Atezolizumab + Bevacizumab
11.27
8.41 – 13.80
Number of Participants Reporting Severe Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) QuestionnaireSecondary· From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)
Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A su
Cycle 1 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
39
Cycle 2 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
33
Cycle 3 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
23
Cycle 4 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
30
Cycle 5 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
23
Cycle 6 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
22
Cycle 7 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
17
Cycle 8 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
14
Number of Participants Reporting Very Severe Symptoms in PRO-CTCAE QuestionnaireSecondary· From Cycle 1 Day 1 to Cycle 63 Day 1 (1 Cycle = 21 days)
Participants self-reported symptomatic AEs using PRO-CTCAE, a validated item bank used to characterize presence, frequency of occurrence, severity, \&/or degree of interference with daily function of 78 patient-reportable symptomatic treatment toxicities. PRO-CTCAE contains questions that are rated either dichotomously (for determination of presence vs. absence) or on a 5-point Likert scale (for determination of frequency of occurrence,severity,\& interference with daily function). Treatment toxicities can occur with observable signs (e.g.,vomiting)/ non-observable symptoms (e.g.,nausea). A su
Cycle 1 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
15
Cycle 2 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
18
Cycle 3 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
12
Cycle 4 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
12
Cycle 5 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
10
Cycle 6 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
11
Cycle 7 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
7
Cycle 8 Day 1
Group
Value
95% CI
Atezolizumab + Bevacizumab
11
Adverse events — posted to ClinicalTrials.gov
Time frame: Other AEs: From initiation of study drug until 30 days after the final dose or initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 47.6 months) SAEs, and All-cause mortality: From initiation of study drug until 90 days after the final dose or initiation of new systemic anti-cancer therapy, whichever occurs first (up to approximately 47.6 months).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer
· Phase 3
· not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce
· Phase 2
· recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec
· Phase 3
· not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Carcinoma, Hepatocellular
Currently open trials in the same condition.
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be
· Phase 2
· recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen
· Phase 1, PHASE2
· recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to
· Phase 2
· recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
· Phase 2
· recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W
· Phase 2
· recruiting
Other Hoffmann-La Roche trials
Trials by the same sponsor.
NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O
· Phase 2
· not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in
· Phase 3
· recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations
· not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
· Phase 3
· recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
· Phase 3
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04487067.